In Section A, members will receive unique doses and schedules of oral ABBV-744 pill to recognize Harmless dosing program. Extra participants might be enrolled in the recognized monotherapy dosign routine. In Phase B, participants will receive oral ruxolitinib and ABBV-744 is going to be specified as "add-on" therapy. In Phase https://abbv-744brd4inhibitormech01356.blogsidea.com/38271861/details-fiction-and-clinical-effectiveness-of-abbv-744-in-aml-patients